Cargando…

Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system

BACKGROUND: The tumor-associated glycoprotein osteopontin (OPN) is discussed as a plasma surrogate marker of tumor hypoxia and as an indicator of the presence of pleural mesothelioma in asbestos-exposed individuals. The clinical introduction of plasma OPN measurements requires the availability of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vordermark, Dirk, Said, Harun M, Katzer, Astrid, Kuhnt, Thomas, Hänsgen, Gabriele, Dunst, Jürgen, Flentje, Michael, Bache, Matthias
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564036/ https://www.ncbi.nlm.nih.gov/pubmed/16911785 http://dx.doi.org/10.1186/1471-2407-6-207

Ejemplares similares

Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines
por: Wohlleben, Gisela, et al.
Publicado: (2015)

Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer
por: Ostheimer, Christian, et al.
Publicado: (2014)

Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer
por: Polat, Bülent, et al.
Publicado: (2017)

Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin
por: Ostheimer, Christian, et al.
Publicado: (2017)

Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells
por: Hahnel, Antje, et al.
Publicado: (2010)

Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients
por: Bache, Matthias, et al.
Publicado: (2010)

Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells
por: Staab, Adrian, et al.
Publicado: (2007)

Potential risk factors for jaw osteoradionecrosis after radiotherapy for head and neck cancer
por: Kuhnt, Thomas, et al.
Publicado: (2016)

Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients
por: Hahnel, Antje, et al.
Publicado: (2012)

Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in – vitro
por: Said, Harun M, et al.
Publicado: (2009)

Distinct effects of rectum delineation methods in 3D-confromal vs. IMRT treatment planning of prostate cancer
por: Guckenberger, Matthias, et al.
Publicado: (2006)

Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer
por: Plumer, Alicia, et al.
Publicado: (2008)

Factors Influencing the Survival Rate of Teeth and Implants in Patients after Tumor Therapy to the Head and Neck Region—Part 1: Tooth Survival
por: Schweyen, Ramona, et al.
Publicado: (2022)

GAPDH is not regulated in human glioblastoma under hypoxic conditions
por: Said, Harun M, et al.
Publicado: (2007)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Parotid gland-recovery after radiotherapy in the head and neck region - 36 months follow-up of a prospective clinical study
por: Hey, Jeremias, et al.
Publicado: (2011)

Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci
por: Djuzenova, Cholpon S, et al.
Publicado: (2013)

Betulinyl Sulfamates as Anticancer Agents and Radiosensitizers in Human Breast Cancer Cells
por: Bache, Matthias, et al.
Publicado: (2015)

Does Intensity Modulated Radiation Therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
por: Guckenberger, Matthias, et al.
Publicado: (2008)

Cancer of the Cervix
Publicado: (1888)

Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity
por: Riemann, Anne, et al.
Publicado: (2018)

Expression of osteopontin and osteonectin in breast cancer.
por: Kim, Y. W., et al.
Publicado: (1998)

Role of osteopontin in cancer development and treatment
por: Yan, Zhihua, et al.
Publicado: (2023)

Socioeconomic disparities in head and neck cancer survival in Germany: a causal mediation analysis using population-based cancer registry data
por: Bedir, Ahmed, et al.
Publicado: (2021)

Smoking and cancer of the cervix.
por: Winkelstein, W.
Publicado: (1981)

CANCER OF THE UTERINE CERVIX
Publicado: (1973)

Circumcision and Cancer of the Cervix
por: Aitken-Swan, Jean, et al.
Publicado: (1965)

Cancer of the Uterine Cervix
por: Duarte-Franco, Eliane, et al.
Publicado: (2004)

Cancer of the Cervix Uteri
por: Oliver, James
Publicado: (1894)

Cancer of the Cervix Uteri
por: Blake, John G.
Publicado: (1881)

Cancer of Cervix in Nullipara
Publicado: (1915)

The Pre-Cancerous Cervix
por: Cunningham, S. A.
Publicado: (1917)

Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
por: Polat, Bülent, et al.
Publicado: (2022)

Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells
por: Güttler, Antje, et al.
Publicado: (2021)

Hypoxia-specific targets in cancer therapy: role of splice variants
por: Vordermark, Dirk
Publicado: (2010)

Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments
por: Evers, Christoph, et al.
Publicado: (2020)

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
por: Vordermark, Dirk, et al.
Publicado: (2005)

Potential of Osteopontin in the Management of Epithelial Ovarian Cancer
por: Cerne, Katarina, et al.
Publicado: (2019)

Osteopontin -- a promising biomarker for cancer therapy
por: Wei, Ran, et al.
Publicado: (2017)

Osteopontin as a Tumor Marker in Ovarian Cancer
por: Rani, Shikha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6av83m89lokr9kfv3oopm40sq5